{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:45:12Z","timestamp":1778568312608,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Adoptive cell therapy with tumor infiltrating lymphocytes is FDA approved for metastatic melanoma. TIL from patients with melanoma and factors relating to growth and reactivity have been studied; however, this has not been explored in patients with epithelial cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Metastatic epithelial tumors resected for TIL growth from 2014 to 2023 were analyzed. Two hundred and ninety-one operations were performed to collect TIL for potential treatment. Of these, 263 harvests were each processed for up to 24 individual fragment cultures and screened for neoantigen recognition of the expressed products of cancer mutations. Patient and tumor characteristics were collected. Endpoints were growth (defined as more than half of all fragment cultures expanded for viable cryopreservation) and patient-specific neoantigen reactivity (release of interferon-\u03b3 in cocultures measured by ELISpot and 4-1BB upregulation on flow cytometry).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>TIL fragments reached adequate growth for screening by 21\u00a0days. Metastatic resections from lung were more likely to grow TIL than all other resection sites combined (95%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0011), while hepatic resections were less likely to grow (69%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). One hundred and thirty-five patients (51%) had highly reactive TIL, 68 (26%) had weakly reactive TIL, and 60 (23%) had TIL with no neoantigen reactivity. Patients with prior exposure to immune checkpoint blockade therapy were less likely to have highly reactive TIL (<jats:italic>p<\/jats:italic>\u2009=\u20090.0325). Metastatic resection site impacted TIL reactivity against neoantigens, with those harvested from the lung more likely to show any reactivity (83%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0180), as well as high reactivity (59%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0066).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Prior immune checkpoint therapies reduced the likelihood of having highly reactive TIL. Neoantigen reactivity was more common in TIL from thoracic resections versus other sites. Conversely, hepatic lesions yielded TIL less likely to grow and with less reactivity. These results contribute to improved strategies for sequencing TIL with other therapies and planning TIL harvests for patients with epithelial cancers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00262-025-04091-3","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:41:16Z","timestamp":1750300876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers"],"prefix":"10.1007","volume":"74","author":[{"given":"Alexandra M.","family":"Gustafson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron J.","family":"Dinerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle J.","family":"Hitscherich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Parkhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunmi","family":"Halas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuong D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Li M.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"Klemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie L.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"1","key":"4091_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"4091_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520","journal-title":"N Engl J Med"},{"issue":"3","key":"4091_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217\u2013226","journal-title":"N Engl J Med"},{"issue":"19","key":"4091_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"1","key":"4091_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23(1):77\u201390","journal-title":"Lancet Oncol"},{"issue":"23","key":"4091_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW et al (2022) Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 387(23):2113\u20132125","journal-title":"N Engl J Med"},{"issue":"16","key":"4091_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N et al (2022) Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol 40(16):1741\u20131754","journal-title":"J Clin Oncol"},{"issue":"6184","key":"4091_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E et al (2014) Cancer Immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184):641\u2013645","journal-title":"Science"},{"issue":"23","key":"4091_CR9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E et al (2016) T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375(23):2255\u20132262","journal-title":"N Engl J Med"},{"issue":"8","key":"4091_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","volume":"33","author":"SL Goff","year":"2010","unstructured":"Goff SL et al (2010) Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 33(8):840\u2013847","journal-title":"J Immunother"},{"issue":"9","key":"4091_CR11","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/j.esmoop.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM et al (2024) Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2212 metastatic breast cancer treated with chemotherapy in the United States. ESMO Open 9(9):103691","journal-title":"ESMO Open"},{"issue":"4","key":"4091_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","volume":"26","author":"ME Dudley","year":"2003","unstructured":"Dudley ME et al (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4):332\u2013342","journal-title":"J Immunother"},{"issue":"3","key":"4091_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran E, Robbins PF, Rosenberg SA (2017) \u201cFinal common pathway\u201d of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18(3):255\u2013262","journal-title":"Nat Immunol"},{"issue":"21","key":"4091_CR14","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T et al (2024) Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer. N Engl J Med 391(21):2014\u20132026","journal-title":"N Engl J Med"},{"issue":"24","key":"4091_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA et al (2022) Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol 40(24):2789\u20132805","journal-title":"J Clin Oncol"},{"issue":"1","key":"4091_CR16","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/jitc-2019-000491","volume":"8","author":"S Garc\u00eda-Mulero","year":"2020","unstructured":"Garc\u00eda-Mulero S et al (2020) Lung metastases share common immune features regardless of primary tumor origin. J Immunother Cancer 8(1):e000491","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4091_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13059-021-02363-6","volume":"22","author":"WJ Ho","year":"2021","unstructured":"Ho WJ et al (2021) Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol 22(1):154","journal-title":"Genome Biol"},{"issue":"5","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q et al (2021) Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov 11(5):1248\u20131267","journal-title":"Cancer Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04091-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:38:30Z","timestamp":1757191110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04091-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04091-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"244"}}